hVIVO (LON:HVO) Shares Pass Below Fifty Day Moving Average – What’s Next?

Shares of hVIVO plc (LON:HVO) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 6.04 and traded as low as GBX 5.50. hVIVO shares last traded at GBX 5.65, with a volume of 2,379,845 shares.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Peel Hunt reaffirmed an “add” rating and set a GBX 10 target price on shares of hVIVO in a research report on Thursday, November 20th. Shore Capital lowered their price objective on hVIVO from GBX 35 to GBX 25 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of GBX 17.50.

hVIVO Stock Down 2.1%

The firm has a market cap of £37.35 million, a P/E ratio of 7.06 and a beta of 0.97. The firm’s 50-day moving average price is GBX 6.01 and its 200 day moving average price is GBX 7.85. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.

Insider Buying and Selling

In other news, insider Yamin Mo’ Khan purchased 3,310,405 shares of the stock in a transaction dated Monday, December 15th. The stock was acquired at an average cost of GBX 6 per share, for a total transaction of £198,624.30. Also, insider Stephen Pinkerton acquired 520,000 shares of hVIVO stock in a transaction that occurred on Monday, December 15th. The shares were purchased at an average price of GBX 6 per share, for a total transaction of £31,200. Company insiders own 4.43% of the company’s stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.